Lung Cancer

Non-small cell lung cancer (NSCLC)
- Advanced NSCLC
  - NSCLC with presence or absence of known EGFR mutation
    - NSCLC with presence or absence of known EGFR mutation
  - NSCLC with presence or absence of known EGFR mutation

Small cell lung cancer (SCLC)
- SCLC
  - Extensive-stage SCLC
    - Either NSCLC or SCLC
      - Metastatic NSCLC or SCLC
        - Lung cancer with brain metastases
          - NSCLC, including neuroendocrine tumors or

Mesothelioma

Lung cancer with brain metastases

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 13, 2020

**ETCTN Trials by Disease/ Treatment Area: Lung Cancer**

- **10266:** A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
- **10313:** A Phase III and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
- ▼ **10327:** A Phase I Trial of MLN0128 (TAK-228) and CB-839 HCL (tetaglenastat) in Advanced NSCLC Patients
- **9989:** A Phase I Trial of AZD9291 and Nectumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
- **10216:** A Phase III Study of AZD9291 (Osimertinib) and CB-839 HCL in Patients with EGFR Mutant Non-Small Cell Lung Cancer
- **10166:** A Phase 2 Study of Atezolizumab and Cobimetinib in PD-L1/PD-1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
- ▼ **10070:** Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors (Dose escalation: solid tumors)
- **10268:** Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small Cell Lung Cancer (Exploratory cohort includes patients with extrapulmonary small cell cancers)
- ▼ **10492:** BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors. Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
- ▼ **10399:** A Phase 1 Study of Entinostat in Combination with Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer
- **9881:** A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, SCLC)
- **10107:** Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Axitinib Ravatinsine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
- * **10286:** Phase II Pilot Evaluation of Tazemetostat in Combination with Cisplatin/Pemetrexed as First-Line Therapy for Pleural Mesothelioma
- **9952:** Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)